Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring
E Jabbour, H Kantarjian - American journal of hematology, 2018 - Wiley Online Library
Disease overview Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with an
incidence of 1‐2 cases per 100 000 adults. It accounts for approximately 15% of newly …
incidence of 1‐2 cases per 100 000 adults. It accounts for approximately 15% of newly …
Standardization and quality control studies of 'real-time'quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease …
J Gabert, E Beillard, VHJ Van der Velden, W Bi… - Leukemia, 2003 - nature.com
Detection of minimal residual disease (MRD) has proven to provide independent prognostic
information for treatment stratification in several types of leukemias such as childhood acute …
information for treatment stratification in several types of leukemias such as childhood acute …
Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring
E Jabbour, H Kantarjian - American journal of hematology, 2020 - Wiley Online Library
Disease overview Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with an
incidence of 1‐2 cases per 100 000 adults. It accounts for approximately 15% of newly …
incidence of 1‐2 cases per 100 000 adults. It accounts for approximately 15% of newly …
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
M Baccarani, G Saglio, J Goldman, A Hochhaus… - Blood, 2006 - ashpublications.org
The introduction of imatinib mesylate (IM) has revolutionized the treatment of chronic
myeloid leukemia (CML). Although experience is too limited to permit evidence-based …
myeloid leukemia (CML). Although experience is too limited to permit evidence-based …
Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring
E Jabbour, H Kantarjian - American journal of hematology, 2016 - Wiley Online Library
Disease overview: Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm with
an incidence of 1‐2 cases per 100,000 adults. It accounts for approximately 15% of newly …
an incidence of 1‐2 cases per 100,000 adults. It accounts for approximately 15% of newly …
Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time'quantitative reverse-transcriptase polymerase …
E Beillard, N Pallisgaard, VHJ Van der Velden, W Bi… - Leukemia, 2003 - nature.com
Real-time quantitative RT-PCR (RQ-PCR) is a sensitive tool to monitor minimal residual
disease (MRD) in leukemic patients through the amplification of a fusion gene (FG) …
disease (MRD) in leukemic patients through the amplification of a fusion gene (FG) …
The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases
A Stengel, W Kern, T Haferlach, M Meggendorfer… - Leukemia, 2017 - nature.com
Alterations in TP53 have been described in many cancer types including hematological
neoplasms. We aimed at comparing TP53 mutations (mut) and deletions (del) in a large …
neoplasms. We aimed at comparing TP53 mutations (mut) and deletions (del) in a large …
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy
A Hochhaus, S Kreil, AS Corbin, P La Rosee… - Leukemia, 2002 - nature.com
Selective inhibition of the BCR-ABL tyrosine kinase by imatinib (STI571, Glivec/Gleevec) is a
promising new therapeutic strategy in patients with chronic myelogenous leukemia (CML) …
promising new therapeutic strategy in patients with chronic myelogenous leukemia (CML) …
Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management
E Jabbour, H Kantarjian - American journal of hematology, 2014 - Wiley Online Library
Disease overview: Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm with
an incidence of 1–2 cases per 100,000 adults, and accounts for∼ 15% of newly diagnosed …
an incidence of 1–2 cases per 100,000 adults, and accounts for∼ 15% of newly diagnosed …
Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV
A Fabarius, A Leitner, A Hochhaus… - Blood, The Journal …, 2011 - ashpublications.org
The prognostic relevance of additional cytogenetic findings at diagnosis of chronic myeloid
leukemia (CML) is unclear. The impact of additional cytogenetic findings at diagnosis on …
leukemia (CML) is unclear. The impact of additional cytogenetic findings at diagnosis on …